ArticleFrontiers in immunology2025
Collectin-11 promotes fibroblast proliferation and modulates their activation status and extracellular matrix synthesis.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Collectin-11 (CL-11), a recently described soluble C-type lectin, has been shown to stimulate cell proliferation in fibroblasts and melanoma cells. However, its broader influence on fibroblast functions and the specific receptors mediating CL-11's effects remain to be elucidated. Methods: The EDU proliferation assay and WB detection of PCNA protein levels were used to evaluate the fibroblast proliferative effect after CL-11 stimulated. The qRT-PCR and WB detection of fibronectin and collagen I were used to evaluate the ECM production. The qRT-PCR detection of Il-6, Il-11, Tnfa, Il1b, Cxcl1, Egf, Tgfb1, Pdgfb were used to evaluate the cytokine production. The WB detection of ERK, AKT, STAT3, mTOR, SMAD2 and ACTIN were used to evaluate the activation of signaling pathway. The WB detection of ERK, AKT, STAT3, mTOR, SMAD2 and ACTIN were used to evaluate the activation of signaling pathway. The immunofluorescence and molecular docking experiments were used to detect the binding of CL-11 to EGFR/TGFRII. Results: In this study, we demonstrate that CL-11 not only promotes fibroblast proliferation but also modulates their activation status and extracellular matrix (ECM) synthesis. Specifically, treatment with recombinant CL-11 (rCL-11) significantly upregulated the production of ECM proteins (fibronectin, collagen I), growth factors (EGF, TGF-β1), and proinflammatory cytokines/chemokines (IL-6, TNF-α, IL-11, IL-1β, CXCL1) in renal fibroblasts. Additionally, rCL-11 activated multiple intracellular signaling pathways, including ERK, AKT/mTOR, STAT3, and SMAD2. Further, EGFR and TGF-βRII were found to be abundantly expressed in renal fibroblasts, and molecular docking analysis along with immunofluorescence/confocal microscopy confirmed CL-11's interaction with these receptors. Discussion: Our findings provide strong evidence that CL-11 plays a critical role in renal fibroblast proliferation and activation via engagement with EGFR and TGF-βRII, shedding light on the mechanisms by which CL-11 stimulates cellular activation and proliferation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.